摘要
目的探讨联合检测中晚期非小细胞肺癌(NSCLC)患者血清癌胚抗原(CEA)、癌抗原125(CA125)和血管内皮生长因子(VEGF)在化疗疗效评估中的价值。方法采用ELISA和免疫放射分析法测定45例中晚期NSCLC患者(肺癌组)化疗前、后血清CEA、CA125和VEGF的水平;以45例健康者为对照组。结果肺癌组血清CEA、CA125和VEGF明显高于对照组(P<0.05);肺癌组CEA、CA125和VEGF在化疗后均低于化疗前(P<0.05)。结论血清CEA、CA125和VEGF水平与肺癌病情变化相关。联合检测血清CEA、CA125和VEGF对评估中晚期NSCLC患者病情及预后有一定的参考价值。
Objective To investigate the value of combined determination of serum carcinoembryonic antigen（CEA）,cancer antigen 125（CA125） and vascular endothelial growth factor（VEGF） in peripheral blood in evaluating chemotherapeutic efficacy in patients with non-small cell lung cancer（NSCLC）. Methods Serum CEA,CA125 and VEGF were determined by ELISA and immunoradiometric assay before and after chemotherapy in 45 patients with advanced NSCLC（group A） and 45 healthy controls（group C）. Results The concentrations of serum CEA,CA125 and VEGF were significantly higher in group A than those in group C（P0.05）,which in group A were remarkably reduced after chemotherapy than those before（P0.05）. Conclusion Combined detection of CEA,CA125 and VEGF is helpful in evaluating the cindition and prognosis of NSCLC patients undergoing chemotherapy.
出处
《江苏医药》
CAS
CSCD
北大核心
2011年第22期2679-2681,共3页
Jiangsu Medical Journal
关键词
非小细胞肺癌
癌胚抗原
癌抗原125
血管内皮生长因子
Non-small cell lung cancer
Carcinoembryonic antigen
Cancer antigen 125
Vascular endothel ial growth factor chemotherapy
